Evozyne
Gary Krishnan serves as the Chief Scientific Officer at Evozyne, bringing a wealth of experience from previous roles at Eli Lilly and Company, where Gary held significant positions including Vice President of Translational Research and Senior Research Fellow. Additionally, Gary previously occupied the role of Chief Scientific Officer at Eli Lilly and Company, demonstrating a strong background in scientific leadership and translational research within the pharmaceutical industry.
This person is not in any teams
Evozyne
1 followers
Evozyne combines evolution and deep learning technology to create highly functional novel proteins — Natural Machines™ — to solve longstanding challenges in therapeutics and sustainability. By amplifying a protein’s function based on the rules of nature, we address complex, high-impact problems. From developing life-changing patient treatments to making carbon capture a reality, Evozyne is committed to making a healthier, more sustainable world.